Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI) Conference 2015: Patient-Focused Drug Development (PFDD)
AuthorPerfetto, Eleanor M.
Oehrlein, Elisabeth Maria
Hanna, Maya L.
Vandigo, Joseph Edward
MetadataShow full item record
Other TitlesM-CERSI Conference 2015: Patient-Focused Drug Development (PFDD)
M-CERSI Conference on Patient-Focused Drug Development
AbstractA movement to include the patient voice in health care research and decision making is underway. In light of broad stakeholder interest in patient-focused drug development (PFDD), a range of stakeholders are considering approaches to increase the scope of PFDD and enhancing patient engagement. On March 9, 2015, the University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI), with the support of many partner organizations, held the “M-CERSI Conference on PatientFocused Drug Development.” The objective was to allow stakeholders from patient groups, the US Food and Drug Administration (FDA), the biopharmaceutical industry, payer, and other organizations to voice their views on, activities in, and aspirations for PFDD. During the day-long program, participants discussed the challenges to successful PFDD including regulatory challenges, the patient and patient advocate role, the emerging payer role, along with future directions and opportunities for collaboration. This document summarizes stakeholders’ perspectives on and understanding of the definition and attributes of PFDD as well as its potential for achieving the goal of including the patient’s voice in drug development. The role of various stakeholders and opportunities for their active participation were outlined. The outputs of the conference included a suggested definition, rubric, and framework for PFDD: Definition: Patient-focused drug development is a formal process by which drug* developers and regulators form a partnership with patients to enhance drug* development, research, regulatory, and reimbursement processes with the patient voice. This partnership engages patients to obtain, as critical input, their views, experiences, and preferences throughout a product’s* lifecycle. Rubric: 1. Patients as Partners: Patients, caregivers, and other relevant people (e.g., people who are at risk for a disease, but do not yet have the disease) are recognized as partners in the drug development process throughout the product life cycle. 2. Continuous Patient Engagement: Patient engagement is continuous, throughout the drug development process and product lifecycle; it is not a one-time or sporadic event. 3. Meaningful Patient Engagement: Patient engagement must be meaningful. That is, it must be a real interaction and dialogue, not a “check-the-box” exercise. Patient input should come from thoughtful dialogue and patients should be able to see how the input they provide is used in the specific studies or aspects of processes. 4. The Right Patients are Engaged: Throughout the process, the affected patient population is well represented, and other relevant populations are considered for engagement. 5. Right Time to Engage: Engagement happens at the appropriate time(s) throughout the process. Conceptual Framework: Building upon previously proposed models and the meeting discussion, a conceptual framework for PFDD emerged. Proposed PFDD Conceptual Framework. Adapted from: Clinical Trials Transformation Initiative’s Patient Groups & Clinical Trials Expert Meeting summary; National Health Council’s Dialogue/Advancing Meaningful Patient Engagement in Drug Research, Development, and Approval; and the model proposed by Perfetto et al. Med Care. 2015 Jan;53(1):9-17
Table of ContentsAbstract; Executive Summary; Session 1: FDA Activities in and Goals for PFDD; Session 2: Patient Activities, Challenges, and Aspirations; Session 3: Current Industry Activities and Plans; Payers: Why They Should Join the Dialogue; Future Directions and Opportunities for Collaboration; Conclusions; Definition for PFDD; A Proposed Rubric – How do we know the patient has been engaged in drug development? References; Appendix A. M-CERSI Conference on PFDD; Appendix B. Example PFDD Meeting
DescriptionHeld on March 9, 2015, the M-CERSI Conference on Patient-Focused Drug Development provided a forum for all patient-focused drug development (PFDD) stakeholders to gather for an open dialogue.
© 2015 University of Maryland, Baltimore, School of Pharmacy
Prescription Drug User Fee Act (PDUFA)
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/10122
Showing items related by title, author, creator and subject.
PATIENTS Day 2019: What Motivates People with Substance Use Disorders to Pursue Treatment? A Patient-Centered Approach to Understanding Patient Experiences and Patient-Provider InteractionsGressler, Laura E.; Natafgi, Nabil; DeForge, Bruce R.; Robinson-Shaneman, Barbarajean; Welsh, Christopher; Shaya, Fadia T. (2019-05-31)
PATIENTS Day 2019: Training for Cardiologists and their Patients about Patient-Centered Outcomes Research (PCOR)Cooke, Catherine E.; Burroughs, Angela; Mullins, C. Daniel; Perfetto, Eleanor M. (2019-05-31)
Healthcare Provider Communication with Young Adults: Patient-Centered Communication, Patient Satisfaction, Patient Trust, Social Support, Self-Care Skills, and Emotional Well-BeingNichols, Helen M.; Sacco, Paul; 0000-0002-6782-0869 (2018)Patient-centered communication is critical to the delivery of quality healthcare services. Although numerous health outcomes have been connected to patient-provider communication, there is limited research that has explored the processes and pathways between communication and health. Research among young adults (ages 26-39 years) is even more scarce, despite findings that health communication does vary with age. This study used data from the 2014 Health Interview National Trends Survey to (1) test a scale of seven items measuring patient-centered communication among young adults age 26 to 39 and (2) explore the relationship between patient-centered communication, patient trust, patient satisfaction, social support, self-care skills, and emotional well-being among young adults age 26 to 39. Exploratory and confirmatory factor analyses were conducted and results showed that a one-factor model of patient-centered communication among young adults fit the data well. In the final regression model, income, history of depression diagnosis, patient-centered communication, patient trust, social support, and patient self-efficacy (self-care skills) were all significantly related to emotional well-being. Post-hoc analyses showed that self-efficacy and patient trust modify the association between general health and emotional well-being. Among respondents who reported poor overall health, increases in self-efficacy and trust in their provider are associated with corresponding improvement in their predicted emotional well-being. This is in contrast to respondents who reported excellent overall health, for whom an improvements in self-efficacy and trust did not have the same effect on predicted emotional well-being. There was a significant interaction between depression and self-efficacy, as respondents who reported being diagnosed with depression showed a stronger relationship between self-efficacy and greater predicted well-being. Post-hoc analyses also showed significant interactions between patient-centered communication, satisfaction, and social support. Respondents who reported lower levels of PCC, showed decreased predicted emotional well-being as their satisfaction and perceived social support increased. These findings suggest the need to explore the means through which communication can impact emotional well-being, specifically among young adults who are in poor health or have a history of depression. Future research should also include longitudinal studies, in order to determine causality and directionality among constructs.